From Surf Wiki (app.surf) — the open knowledge base

Valrubicin

Pharmaceutical drug

| Drugs.com =

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues. Valstar was relaunched on September 3, 2009.

Side effects

Blood in urine
Incontinence
painful or difficult urination
Unusually frequent urination

References

(2015). "Valrubicin in refractory non-muscle invasive bladder cancer". Expert Review of Anticancer Therapy.
U.S. Food and Drug Administration]] News. The MQN Weekly Bulletin, Jan. 11, 2008
(2009-09-03). "Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors".

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

anthracyclines topoisomerase-inhibitors trifluoromethyl-compounds acetamides withdrawn-drugs

Want to explore this topic further?

Ask Mako anything about Valrubicin — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report